Sepracor Plans April 4 Lunesta Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Sepracor will launch the insomnia agent upon same-day publication of the final rule designating Lunesta as a Schedule IV controlled substance. More than 40,000 retail pharmacies already have placed orders for eszopiclone, the company says.